Search: (WFRF:(Borg Philip)) srt2:(2015-2019) >
Tumour Growth Rate ...
Tumour Growth Rate as a validated early radiological biomarker able to reflect treatment-induced changes in Neuroendocrine Tumours : the GREPONET-2 study
-
Lamarca, Angela (author)
-
Ronot, Maxime (author)
-
Moalla, Salma (author)
-
show more...
-
- Crona, Joakim (author)
- Uppsala universitet,Endokrin tumörbiologi
-
Opalinska, Marta (author)
-
Lopez Lopez, Carlos (author)
-
Pezzutti, Daniela (author)
-
Najran, Pavan (author)
-
Carvalho, Luciana Franco do Prado de (author)
-
Bezerra, Regis Otaviano Franca (author)
-
Borg, Philip (author)
-
Vietti Violi, Naik (author)
-
Vidal Trueba, Hector (author)
-
de Mestier, Louis (author)
-
Schaefer, Niklaus (author)
-
Baudin, Eric (author)
-
- Sundin, Anders, 1954- (author)
- Uppsala universitet,Radiologi
-
Costa, Frederico P (author)
-
Pavel, Marianne (author)
-
Dromain, Clarisse (author)
-
show less...
-
(creator_code:org_t)
- 2019
- 2019
- English.
-
In: Clinical Cancer Research. - 1078-0432 .- 1557-3265. ; 15:25, s. 6692-6699
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- PURPOSE: TGR represents the percentage change in tumour volume per month (%/m). Previous results from the GREPONET study showed that TGR measured after 3 months (TGR3m) of starting systemic treatment (ST) or watch and wait (WW) was an early biomarker predicting progression-free survival (PFS) in NETs.EXPERIMENTAL DESIGN: Pts from7 centres with advanced grade(G) 1/2 NETs from the pancreas(P)/small bowel(SB) initiating ST/WW were eligible. Computed tomography (CT) / magnetic resonance imaging (MRI) performed at pre-baseline, baseline and 3(+/-1) months of study entry were retrospectively reviewed. Aim-1: explore treatment-induced changes in TGR (ΔTGR3m-BL) (paired T-test) and Aim-2: validate TGR3m (<0.8%/m vs ≥0.8%/m) as an early biomarker in an independent cohort (Kaplan-Meier/Cox Regression).RESULTS: Out of 785 pts screened, 127 were eligible. Mean (SD) TGR0 and TGR3m were 5.4%/m (14.9) and -1.4%/m (11.8), respectively. Mean(SD) ΔTGR3m-BL paired-difference was -6.8%/m(19.3) (p<0.001). Most marked ΔTGR3m-BL (mean (SD);p) were identified with targeted therapies (-11.3%/m(4.7);0.0237) and chemotherapy (-7.9%/m(3.4);0.0261). Multivariable analysis confirmed the absence of previous treatment (Odds Ratio (OR) 4.65 (95%CI 1.31-16.52); p-value0.018) and low TGR3m (continuous variable; OR 1.09 (95%CI 1.01-1.19); p-value0.042) to be independent predictors of radiological objective response. When the multivariable Cox Regression was adjusted to grade (p-value 0.004) and stage (p-value0.017), TGR3m≥0.8 (vs.<0.8) maintained its significance (p<0.001), while TGR0 and ΔTGR3m-BL did not. TGR3m was confirmed as an independent prognosis factor for PFS (external validation; Aim-2) (multivariable HR 2.21 (95%CI 1.21-3.70); p-value0.003).CONCLUSIONS: TGR has a role as biomarker for monitoring response to therapy for early prediction of PFS and radiological objective response.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Lamarca, Angela
-
Ronot, Maxime
-
Moalla, Salma
-
Crona, Joakim
-
Opalinska, Marta
-
Lopez Lopez, Car ...
-
show more...
-
Pezzutti, Daniel ...
-
Najran, Pavan
-
Carvalho, Lucian ...
-
Bezerra, Regis O ...
-
Borg, Philip
-
Vietti Violi, Na ...
-
Vidal Trueba, He ...
-
de Mestier, Loui ...
-
Schaefer, Niklau ...
-
Baudin, Eric
-
Sundin, Anders, ...
-
Costa, Frederico ...
-
Pavel, Marianne
-
Dromain, Clariss ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Clinical Cancer ...
- By the university
-
Uppsala University